Chong Kun Dang Pharmaceutical Corp.
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT05544214
- Locations
- π°π·
Korea University Anam Hospital, Seoul, Korea, Republic of
Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-828 in Healthy Subjects
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Drug: D064+D701Drug: CKD-828 Formulation 1Drug: CKD-828 Formulation 2
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT05540912
- Locations
- π°π·
Central Hospital, Ansan-si, Korea, Republic of
A Study to Evaluate the Relative Bioavailability of Formulations of CKD-510 and to Assess the Effect of Food on the CKD-510 Tablet Formulation in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: CKD-510 capsule (reference)Drug: CKD-510 tablet (test)
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 16
- Registration Number
- NCT05526742
- Locations
- πΊπΈ
Clinical Pharmacology Unit, Cincinnati, Ohio, United States
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy
Phase 3
Recruiting
- Conditions
- Essential Hypertension
- Interventions
- Drug: D012, placebo of D064, placebo of D701Drug: D064, D701, placebo of D012
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 108
- Registration Number
- NCT05526703
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Pharmacokinetics and Safety/Tolerability Profile of CKD-379
Phase 1
Completed
- Conditions
- Type II Diabetes Mellitus
- Interventions
- Drug: CKD-379 IDrug: CKD-379 IIDrug: D759+D745+D150
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT05452525
- Locations
- π°π·
Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of
A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions
Phase 1
Completed
- Conditions
- Type2Diabetes
- Interventions
- Drug: CKD-393(2)Drug: CKD-501, D759, D150, D029
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 31
- Registration Number
- NCT05347576
- Locations
- π°π·
Chonbuk National University Hospital, Jeonju, Korea, Republic of
Study to Evaluate the Safety and Pharmacokinetics of CKD-331
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 47
- Registration Number
- NCT05335044
- Locations
- π°π·
H plus Yangji hospital, Seoul, Korea, Republic of
Study to Evaluate the Food Effect on Pharmacokinetics Profile and Safety of CKD-393
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 28
- Registration Number
- NCT05274880
- Locations
- π°π·
Korea University Guro Hospital, Seoul, Korea, Republic of
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg
Phase 1
Completed
- Conditions
- Hypertension and Dyslipidemia
- Interventions
- Drug: CKD-386(3)Drug: D013, D326, D337
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 64
- Registration Number
- NCT05245084
- Locations
- π°π·
H plus Yangji hospital, Seoul, Korea, Republic of
CKD-506 Drug-Drug Interaction Study in Healthy Male Subjects
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 17
- Registration Number
- NCT05238948
- Locations
- π³π±
PRA Health Sciences, Groningen, Netherlands
Β© Copyright 2025. All Rights Reserved by MedPath